α-KG and NMN Combination for Bone Loss and Marrow Adiposity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging causes significant changes in the skeleton, characterized by a decrease in trabecular bone and an increase in marrow adiposity, leading to osteoporosis and obesity, which are major health concerns affecting millions worldwide, and existing treatments are inadequate.
Innovation Solution
Administering therapeutically effective amounts of alpha-ketoglutarate (α-KG) and nicotinamide mononucleotide (NMN) synergistically to promote osteogenic differentiation, inhibit adipogenic differentiation, increase trabecular bone, and reduce bone marrow adiposity, thereby addressing skeletal aging, osteoporosis, and obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for skeletal aging, osteoporosis or obesity, then some symptomatic relief may be achieved, but the underlying epigenetic alterations and stem cell exhaustion are not effectively addressed, leading to limited long-term efficacy
Solution Approach 1:
The patent uses epigenetic modifiers (HDAC inhibitors, DNA methyltransferase inhibitors) as intermediary agents that mediate between the administered compounds (α-KG, NMN, spermidine) and the target stem cells, restoring their function without directly modifying the stem cells themselves. This indirect approach enhances long-term efficacy while maintaining treatment simplicity
Solution Approach 2:
The patent changes the biochemical parameters within stem cells by introducing compounds that alter epigenetic states (histone acetylation, DNA methylation) and metabolic status (NAD+ levels, polyamine content). These parameter changes restore stem cell function and differentiate them toward osteogenic lineages, providing sustained therapeutic effects
2Quantity of substance
If the focus is placed on treating bone loss alone, then bone mass may be partially preserved, but the associated marrow adiposity and systemic metabolic effects are neglected, reducing overall therapeutic benefit
Solution Approach 1:
The patent employs multi-functional compounds that simultaneously address multiple aspects of the disease: α-KG and NMN not only promote osteogenesis and increase bone mass but also inhibit adipogenesis, reduce marrow adiposity, improve metabolic health, and enhance stem cell function. This multi-functionality provides comprehensive therapeutic benefits beyond bone mass preservation alone
Solution Approach 2:
The patent segments the therapeutic approach into distinct mechanistic pathways: (1) epigenetic modulation, (2) metabolic enhancement, (3) stem cell differentiation guidance. By targeting multiple segments simultaneously, the treatment comprehensively addresses bone loss, adiposity, and systemic metabolic effects
Data Source
AI summary
Methods are provided for treating skeletal aging, osteoporosis and obesity in a subject by therapeutically effective amounts of a combination of alpha-ketoglutarate (α-KG) and nicotinamide mononucleotide (NMN). The therapeutically effective amounts are synergistic in treating skeletal aging, osteoporosis or obesity. Compositions containing both alpha-ketoglutarate (α-KG) and nicotinamide mononucleotide (NMN) are described.